fluoxetine has been researched along with Disease Exacerbation in 16 studies
Fluoxetine: The first highly specific serotonin uptake inhibitor. It is used as an antidepressant and often has a more acceptable side-effects profile than traditional antidepressants.
fluoxetine : A racemate comprising equimolar amounts of (R)- and (S)-fluoxetine. A selective serotonin reuptake inhibitor (SSRI), it is used (generally as the hydrochloride salt) for the treatment of depression (and the depressive phase of bipolar disorder), bullimia nervosa, and obsessive-compulsive disorder.
N-methyl-3-phenyl-3-[4-(trifluoromethyl)phenoxy]propan-1-amine : An aromatic ether consisting of 4-trifluoromethylphenol in which the hydrogen of the phenolic hydroxy group is replaced by a 3-(methylamino)-1-phenylpropyl group.
| Excerpt | Relevance | Reference |
|---|---|---|
| " The aim of this study was to assess the antiarthritic potential of 2 SSRIs, fluoxetine and citalopram, in murine collagen-induced arthritis (CIA) and in a human ex vivo disease model of rheumatoid arthritis (RA)." | 7.76 | Fluoxetine and citalopram exhibit potent antiinflammatory activity in human and murine models of rheumatoid arthritis and inhibit toll-like receptors. ( Brennan, F; Gregory, B; Medghalchi, M; Sacre, S; Williams, R, 2010) |
| "The objective was to present naturalistic 1-year follow-up information of 96 child and adolescent outpatients with major depressive disorder who had been randomized in an 8-week double-blind, placebo-controlled trial of fluoxetine." | 5.08 | Fluoxetine in child and adolescent depression: acute and maintenance treatment. ( Carmody, T; Emslie, GJ; Kowatch, RA; Mayes, TL; Rush, AJ; Weinberg, WA, 1998) |
| " The aim of this study was to assess the antiarthritic potential of 2 SSRIs, fluoxetine and citalopram, in murine collagen-induced arthritis (CIA) and in a human ex vivo disease model of rheumatoid arthritis (RA)." | 3.76 | Fluoxetine and citalopram exhibit potent antiinflammatory activity in human and murine models of rheumatoid arthritis and inhibit toll-like receptors. ( Brennan, F; Gregory, B; Medghalchi, M; Sacre, S; Williams, R, 2010) |
| "Two individuals from a large HD pedigree with a very high prevalence of obsessive-compulsive disorder (OCD) have been treated with fluoxetine, an SSRI." | 3.71 | Fluoxetine in the treatment of Huntington's disease. ( Daniele, F; De Marchi, N; Ragone, MA, 2001) |
| "Fluoxetine treatment showed protective effect against SI, AD and prevents exacerbation of CVD." | 1.72 | Fluoxetine ameliorates Alzheimer's disease progression and prevents the exacerbation of cardiovascular dysfunction of socially isolated depressed rats through activation of Nrf2/HO-1 and hindering TLR4/NLRP3 inflammasome signaling pathway. ( Aboutaleb, AS; Abu-Elfotuh, K; Al-Najjar, AH; Badawi, GA; Mohammed, AA, 2022) |
| "To determine whether SSRIs impact disease progression, fluoxetine (Prozac, 5 or 10 mg/kg) was administered to mutant superoxide dismutase 1 (SOD1) mice during one of three age ranges: neonatal [postnatal day (P)5-11], adult presymptomatic (P30 to end stage), and adult symptomatic (P70 to end stage)." | 1.40 | Effect of fluoxetine on disease progression in a mouse model of ALS. ( Heckman, CJ; Kajtaz, E; Kocevar, EJ; Koschnitzky, JE; Lukas, TJ; Mayers, WF; Quinlan, KA; Siddique, T, 2014) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (6.25) | 18.2507 |
| 2000's | 5 (31.25) | 29.6817 |
| 2010's | 7 (43.75) | 24.3611 |
| 2020's | 3 (18.75) | 2.80 |
| Authors | Studies |
|---|---|
| Abu-Elfotuh, K | 1 |
| Al-Najjar, AH | 1 |
| Mohammed, AA | 1 |
| Aboutaleb, AS | 1 |
| Badawi, GA | 1 |
| Chataway, J | 2 |
| De Angelis, F | 1 |
| Connick, P | 1 |
| Parker, RA | 2 |
| Plantone, D | 2 |
| Doshi, A | 2 |
| John, N | 1 |
| Stutters, J | 2 |
| MacManus, D | 2 |
| Prados Carrasco, F | 1 |
| Barkhof, F | 2 |
| Ourselin, S | 1 |
| Braisher, M | 1 |
| Ross, M | 1 |
| Cranswick, G | 1 |
| Pavitt, SH | 1 |
| Giovannoni, G | 1 |
| Gandini Wheeler-Kingshott, CA | 1 |
| Hawkins, C | 1 |
| Sharrack, B | 1 |
| Bastow, R | 1 |
| Weir, CJ | 2 |
| Stallard, N | 1 |
| Chandran, S | 1 |
| Solanky, BS | 1 |
| John, NA | 1 |
| DeAngelis, F | 1 |
| Prados, F | 1 |
| Schneider, T | 1 |
| Monteverdi, A | 1 |
| Marshall, I | 1 |
| Gandini Wheeler-Kingshott, CAM | 1 |
| Rami, M | 1 |
| Guillamat-Prats, R | 1 |
| Rinne, P | 1 |
| Salvermoser, M | 1 |
| Ring, L | 1 |
| Bianchini, M | 1 |
| Blanchet, X | 1 |
| Megens, RTA | 1 |
| Döring, Y | 1 |
| Walzog, B | 1 |
| Soehnlein, O | 1 |
| Weber, C | 1 |
| Faussner, A | 1 |
| Steffens, S | 1 |
| Aguiar, JC | 1 |
| Gomes, EP | 1 |
| Fonseca-Silva, T | 1 |
| Velloso, NA | 1 |
| Vieira, LT | 1 |
| Fernandes, MF | 1 |
| Santos, SH | 1 |
| Neto, JF | 1 |
| De-Paula, AM | 1 |
| Guimarães, AL | 1 |
| Cambron, M | 1 |
| Mostert, J | 1 |
| Haentjens, P | 1 |
| D'Hooghe, M | 1 |
| Nagels, G | 1 |
| Willekens, B | 1 |
| Heersema, D | 1 |
| Debruyne, J | 1 |
| Van Hecke, W | 1 |
| Algoed, L | 1 |
| De Klippel, N | 1 |
| Fosselle, E | 1 |
| Laureys, G | 1 |
| Merckx, H | 1 |
| Van Wijmeersch, B | 1 |
| Vanopdenbosch, L | 1 |
| Verhagen, W | 1 |
| Hupperts, R | 1 |
| Hengstman, G | 1 |
| Michiels, V | 1 |
| Van Merhaegen-Wieleman, A | 1 |
| De Keyser, J | 1 |
| Koschnitzky, JE | 1 |
| Quinlan, KA | 1 |
| Lukas, TJ | 1 |
| Kajtaz, E | 1 |
| Kocevar, EJ | 1 |
| Mayers, WF | 1 |
| Siddique, T | 1 |
| Heckman, CJ | 1 |
| Sacre, S | 1 |
| Medghalchi, M | 1 |
| Gregory, B | 1 |
| Brennan, F | 1 |
| Williams, R | 1 |
| Kubera, M | 1 |
| Grygier, B | 1 |
| Wrona, D | 1 |
| Rogóż, Z | 1 |
| Roman, A | 1 |
| Basta-Kaim, A | 1 |
| Budziszewska, B | 1 |
| Leskiewicz, M | 1 |
| Jantas, D | 1 |
| Nowak, W | 1 |
| Maes, M | 1 |
| Lason, W | 1 |
| Sahu, JK | 1 |
| Singhi, P | 1 |
| Malhotra, S | 1 |
| Quitkin, FM | 2 |
| Petkova, E | 1 |
| McGrath, PJ | 1 |
| Taylor, B | 1 |
| Beasley, C | 1 |
| Stewart, J | 1 |
| Amsterdam, J | 1 |
| Fava, M | 2 |
| Rosenbaum, J | 1 |
| Reimherr, F | 1 |
| Fawcett, J | 1 |
| Chen, Y | 1 |
| Klein, D | 1 |
| Vogel, G | 1 |
| Peer, D | 1 |
| Dekel, Y | 1 |
| Melikhov, D | 1 |
| Margalit, R | 1 |
| Cusin, C | 1 |
| Amsterdam, JD | 1 |
| Reimherr, FW | 1 |
| Beasley, CM | 1 |
| Rosenbaum, JF | 1 |
| Perlis, RH | 1 |
| Emslie, GJ | 1 |
| Rush, AJ | 1 |
| Weinberg, WA | 1 |
| Kowatch, RA | 1 |
| Carmody, T | 1 |
| Mayes, TL | 1 |
| De Marchi, N | 1 |
| Daniele, F | 1 |
| Ragone, MA | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Multi-arm Phase IIB Randomised, Double Blind Placebo-controlled Clinical Trial Comparing the Efficacy of Three Neuroprotective Drugs in Secondary Progressive Multiple Sclerosis.[NCT01910259] | Phase 2 | 445 participants (Actual) | Interventional | 2014-12-18 | Completed | ||
| Clinical Study Evaluating the Efficacy of Nitazoxanide and Escitalopram as Adjuvant Therapies in Patients With Rheumatoid Arthritis[NCT05480878] | Phase 3 | 90 participants (Actual) | Interventional | 2022-12-02 | Completed | ||
| Prospective 24-week Study, Comparing Clinical Outcomes Between Switching Antidepressants and Maintaining the Same Antidepressant in Patients With Major Depressive Disorder Who do Not Show a 20% Reduction in Symptoms at Week 2[NCT00519012] | Phase 4 | 200 participants (Anticipated) | Interventional | 2007-08-31 | Recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
5 trials available for fluoxetine and Disease Exacerbation
| Article | Year |
|---|---|
Efficacy of three neuroprotective drugs in secondary progressive multiple sclerosis (MS-SMART): a phase 2b, multiarm, double-blind, randomised placebo-controlled trial.
Topics: Administration, Oral; Adult; Amiloride; Brain; Disease Progression; Double-Blind Method; Female; Flu | 2020 |
NAA is a Marker of Disability in Secondary-Progressive MS: A Proton MR Spectroscopic Imaging Study.
Topics: Adult; Amiloride; Aspartic Acid; Biomarkers; Child, Preschool; Cohort Studies; Cross-Sectional Studi | 2020 |
Fluoxetine in progressive multiple sclerosis (FLUOX-PMS): study protocol for a randomized controlled trial.
Topics: Adult; Aged; Belgium; Brain; Clinical Protocols; Cognition; Disability Evaluation; Disease Progressi | 2014 |
When should a trial of fluoxetine for major depression be declared failed?
Topics: Adolescent; Adult; Aged; Depressive Disorder; Disease Progression; Double-Blind Method; Drug Adminis | 2003 |
Fluoxetine in child and adolescent depression: acute and maintenance treatment.
Topics: Acute Disease; Adolescent; Antidepressive Agents, Second-Generation; Anxiety; Chi-Square Distributio | 1998 |
11 other studies available for fluoxetine and Disease Exacerbation
| Article | Year |
|---|---|
Fluoxetine ameliorates Alzheimer's disease progression and prevents the exacerbation of cardiovascular dysfunction of socially isolated depressed rats through activation of Nrf2/HO-1 and hindering TLR4/NLRP3 inflammasome signaling pathway.
Topics: Alzheimer Disease; Animals; Antidepressive Agents; Antioxidants; Behavior, Animal; Biogenic Monoamin | 2022 |
Chronic Intake of the Selective Serotonin Reuptake Inhibitor Fluoxetine Enhances Atherosclerosis.
Topics: Animals; Aorta; Aortic Diseases; Atherosclerosis; Blood Platelets; Capillary Permeability; Carotid A | 2018 |
Fluoxetine reduces periodontal disease progression in a conditioned fear stress model in rats.
Topics: Alveolar Bone Loss; Animals; Anxiety; Chronic Periodontitis; Conditioning, Psychological; Disease Mo | 2013 |
Effect of fluoxetine on disease progression in a mouse model of ALS.
Topics: Amyotrophic Lateral Sclerosis; Animals; Antidepressive Agents, Second-Generation; Behavior, Animal; | 2014 |
Fluoxetine and citalopram exhibit potent antiinflammatory activity in human and murine models of rheumatoid arthritis and inhibit toll-like receptors.
Topics: Animals; Anti-Inflammatory Agents; Arthritis, Experimental; Arthritis, Rheumatoid; Cells, Cultured; | 2010 |
Stimulatory effect of antidepressant drug pretreatment on progression of B16F10 melanoma in high-active male and female C57BL/6J mice.
Topics: Animals; Antidepressive Agents; Cell Line, Tumor; Cytokines; Cytotoxicity Tests, Immunologic; Desipr | 2011 |
Late occurrence of isolated obsessive-compulsive behavior in a boy with Wilson's Disease on treatment.
Topics: Antidepressive Agents, Second-Generation; Child; Disease Progression; Fluoxetine; Hepatolenticular D | 2013 |
Neuroscience. Depression drugs' powers may rest on new neurons.
Topics: Animals; Antidepressive Agents; Antidepressive Agents, Second-Generation; Antidepressive Agents, Tri | 2003 |
Fluoxetine inhibits multidrug resistance extrusion pumps and enhances responses to chemotherapy in syngeneic and in human xenograft mouse tumor models.
Topics: Animals; Antineoplastic Agents; Breast Neoplasms; Carcinoma, Lewis Lung; Cell Line, Tumor; Disease P | 2004 |
Early symptomatic worsening during treatment with fluoxetine in major depressive disorder: prevalence and implications.
Topics: Adult; Clinical Trials as Topic; Depressive Disorder, Major; Disease Progression; Female; Fluoxetine | 2007 |
Fluoxetine in the treatment of Huntington's disease.
Topics: Affect; Aggression; Antidepressive Agents, Second-Generation; Cognition Disorders; Disease Progressi | 2001 |